Scinai Immunotherapeutics (SCNI) Shares Outstanding (2014 - 2026)

Scinai Immunotherapeutics has reported Shares Outstanding (Entity) for 13 years, with the latest figure at $378.7 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 96.23% year-over-year to $378.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $378.7 million (up 96.23% YoY) and the FY2025 annual result came in at $233.5 million, up 189.55% from the prior year.
• Shares Outstanding (Entity) climbed to $378.7 million in Q1 2026 per SCNI's latest filing, from $233.5 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $378.7 million in Q1 2026 and troughed at $1.9 million in Q1 2022.
• A 5-year average of $78.7 million and a median of $27.7 million in 2023 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) surged 33.57% in 2022, then soared 1964.13% in 2024.
• Over 5 years, Shares Outstanding (Entity) stood at $1.9 million in 2022, then soared by 107.22% to $3.9 million in 2023, then jumped by 1964.13% to $80.6 million in 2024, then surged by 189.55% to $233.5 million in 2025, then jumped by 62.17% to $378.7 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $378.7 million, $233.5 million, and $159.1 million for Q1 2026, Q4 2025, and Q2 2025 respectively.